CoChat

Process Parameter Development for the Scaled Generation of Stem Cell-Derived Pancreatic Endocrine Cells

Iworima, Diepiriye G., Rieck, Sebastian, Kieffer, Timothy J. · 2021 · Stem Cells Translational Medicine
Cited by 18

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Diabetes is a debilitating disease characterized by high blood glucose levels. The global prevalence of this disease has been projected to reach 700 million adults by the year 2045. Type 1 diabetes represents about 10% of the reported cases of diabetes. Although islet transplantation can be a highly effective method to treat type 1 diabetes, its widespread application is limited by the paucity of cadaveric donor islets. The use of pluripotent stem cells as an unlimited cell source to generate insulin-producing cells for implant is a promising alternative for treating diabetes. However, to be clinically relevant, it is necessary to manufacture these stem cell-derived cells at sufficient scales. Significant advances have been made in differentiation protocols used to generate stem cell-derived cells capable of reversing diabetes in animal models and for testing in clinical trials. We discuss the potential of both stem cell-derived pancreatic progenitors and more matured insulin-producing cells to treat diabetes. We discuss the need for rigorous bioprocess parameter optimization and identify some critical process parameters and strategies that may influence the critical quality attributes of the cells with the goal of facilitating scalable manufacturing of human pluripotent stem cell-derived pancreatic endocrine cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/sctm.21-0161

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 77

  1. IDF, 2019, IDF Diabetes Atlas 9th edition 2019
  2. Bommer, 2018, Global economic burden of diabetes in adults: projections from 2015 to 2030, Diabetes Care, 41, 963, 10.2337/dc17-1962 · DOI · Paper page
  3. Bliss, 1982, Banting's, Best's and Collip's accounts of the discovery of insulin, Bull Hist Med, 56, 554
  4. Shapiro, 2000, Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med, 343, 230, 10.1056/NEJM200007273430401 · DOI · Paper page
  5. Andres, 2016, Clinical islet isolation and transplantation outcomes with deceased cardiac death donors are similar to neurological determination of death donors, Transpl Int, 29, 34, 10.1111/tri.12650 · doi:10.1111/tri.12650
  6. Markmann, 2003, The use of non-heart-beating donors for isolated pancreatic islet transplantation, Transplantation, 75, 1423, 10.1097/01.TP.0000061119.32575.F4 · DOI · Paper page
  7. D'Amour, 2006, Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells, Nat Biotechnol, 24, 1392, 10.1038/nbt1259 · DOI · Paper page
  8. Henry, 2018, Initial clinical evaluation of VC-01TM combination product—a stem cell–derived islet replacement for type 1 diabetes (T1D), Diabetes, 67, 10.2337/db18-138-OR · DOI · Paper page
  9. Pullen, 2018, Cell-derived pancreatic progenitor cells have now been transplanted into patients: report from IPITA 2018, Am J Transplant, 18, 1581, 10.1111/ajt.14954 · DOI · Paper page
  10. Keymeulen, 2021, 196-LB: stem cell-derived islet replacement therapy (VC-02) demonstrates production of C-peptide in patients with type 1 diabetes (T1D) and hypoglycemia unawareness, Diabetes, 70, 10.2337/db21-196-LB · DOI
  11. Schulz, 2012, A scalable system for production of functional pancreatic progenitors from human embryonic stem cells, PLoS One, 7, 10.1371/journal.pone.0037004 · DOI · Paper page
  12. Saber, 2018, Sex differences in maturation of human embryonic stem cell–derived β cells in mice, Endocrinology, 159, 1827, 10.1210/en.2018-00048 · DOI · Paper page
  13. Bruin, 2016, Hypothyroidism impairs human stem cell-derived pancreatic progenitor cell maturation in mice, Diabetes, 65, 1297, 10.2337/db15-1439 · DOI · Paper page
  14. Bruin, 2015, Accelerated maturation of human stem cell-derived pancreatic progenitor cells into insulin-secreting cells in immunodeficient rats relative to mice, Stem Cell Rep, 5, 1081, 10.1016/j.stemcr.2015.10.013 · DOI · Paper page
  15. Millman, 2016, Generation of stem cell-derived β-cells from patients with type 1 diabetes, Nat Commun, 7
  16. Wang, 2014, Differentiation of iPSCs into insulin-producing cells via adenoviral transfection of PDX-1, NeuroD1 and MafA, Diabetes Res Clin Pract, 104, 383, 10.1016/j.diabres.2014.03.017 · DOI
  17. Saxena, 2016, A programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cells, Nat Commun, 7, 1, 10.1038/ncomms11247 · DOI
  18. Zhu, 2019, Targeted derivation of organotypic glucose- and GLP-1-responsive β cells prior to transplantation into diabetic recipients, Stem Cell Rep, 13, 307, 10.1016/j.stemcr.2019.07.006 · DOI
  19. Vertex Announces FDA, 2021, Clearance of investigational new drug (IND) application for VX-880, a novel cell therapy for the treatment of Type 1 diabetes (T1D) | Vertex Newsroom
  20. Shapiro, 2017, Clinical pancreatic islet transplantation, Nat Rev Endocrinol, 13, 268, 10.1038/nrendo.2016.178 · DOI · Paper page
  21. Docherty, 2007, Embryonic stem cell therapy for diabetes mellitus, Semin Cell Dev Biol, 18, 827, 10.1016/j.semcdb.2007.09.009 · DOI
  22. Lock, 2007, Stem/progenitor cell sources of insulin-producing cells for the treatment of diabetes, Tissue Eng, 13, 1399, 10.1089/ten.2007.0047 · DOI · Paper page
  23. Lipsitz, 2016, Quality cell therapy manufacturing by design, Nat Biotechnol, 34, 393, 10.1038/nbt.3525 · DOI · Paper page
  24. Witcher, 2020, Why controlling CQAs isn't good enough for gene cell therapies
  25. Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
  26. Yu, 2007, Induced pluripotent stem cell lines derived from human somatic cells, Science (80-), 318, 1917, 10.1126/science.1151526 · DOI · Paper page
  27. Chin, 2009, Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures, Cell Stem Cell, 5, 111, 10.1016/j.stem.2009.06.008 · DOI · Paper page
  28. Deng, 2009, Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming, Nat Biotechnol, 27, 353, 10.1038/nbt.1530 · DOI · Paper page
  29. Kim, 2011, Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells, Nat Biotechnol, 29, 1117, 10.1038/nbt.2052 · DOI · Paper page
  30. Yamanaka, 2012, Induced pluripotent stem cells: past, present, and future, Cell Stem Cell, 10, 678, 10.1016/j.stem.2012.05.005 · DOI · Paper page
  31. Moradi, 2019, Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations, Stem Cell Res Ther, 10, 1, 10.1186/s13287-019-1455-y · DOI · Paper page
  32. Stevens, 2018, Human pluripotent stem cell-derived engineered tissues: clinical considerations, Cell Stem Cell, 22, 294, 10.1016/j.stem.2018.01.015 · DOI · Paper page
  33. Stacey, 2019, Stem cell culture conditions and stability: a joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform, Regen Med, 14, 243, 10.2217/rme-2019-0001 · DOI
  34. 2007, Why do scientists need many lines of embryonic stem cells?, Nat Rep Stem Cells
  35. Beers, 2012, Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions, Nat Protoc, 7, 2029, 10.1038/nprot.2012.130 · DOI · Paper page
  36. Zakrzewski, 2019, Stem cells: past, present, and future, Stem Cell Res Ther, 10, 1, 10.1186/s13287-019-1165-5 · DOI · Paper page
  37. Bai, 2015, Temporal analysis of genome alterations induced by single-cell passaging in human embryonic stem cells, Stem Cells Dev, 24, 653, 10.1089/scd.2014.0292 · DOI · Paper page
  38. Borys, 2021, Overcoming bioprocess bottlenecks in the large-scale expansion of high-quality hiPSC aggregates in vertical-wheel stirred suspension bioreactors, Stem Cell Res Ther, 12, 55, 10.1186/s13287-020-02109-4 · DOI · Paper page
  39. Cruvinel, 2020, Long-term single-cell passaging of human iPSC fully supports pluripotency and high-efficient trilineage differentiation capacity, SAGE open Med, 8, 10.1177/2050312120966456 · DOI
  40. Thomson, 2008, Human embryonic stem cells passaged using enzymatic methods retain a normal karyotype and express CD30, Cloning Stem Cells, 10, 89, 10.1089/clo.2007.0072 · DOI
  41. Manstein, 2021, High density bioprocessing of human pluripotent stem cells by metabolic control and in silico modeling, Stem Cells Translational Medicine, 10, 1063, 10.1002/sctm.20-0453 · DOI · Paper page
  42. Sahabian, 2021, Production and cryopreservation of definitive endoderm from human pluripotent stem cells under defined and scalable culture conditions, Nat Protoc, 16, 1581, 10.1038/s41596-020-00470-5 · DOI
  43. Chen, 2010, Actin-myosin contractility is responsible for thcelle reduced viability of dissociated human embryonic stem cells, Cell Stem Cell, 7, 240, 10.1016/j.stem.2010.06.017 · DOI · Paper page
  44. Lipsitz, 2018, Chemically controlled aggregation of pluripotent stem cells, Biotechnol Bioeng, 115, 2061, 10.1002/bit.26719 · DOI · Paper page
  45. Chen, 2021, A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells, Nat Methods, 18, 528, 10.1038/s41592-021-01126-2 · DOI · Paper page
  46. Komatsu, 2017, Oxygen environment and islet size are the primary limiting factors of isolated pancreatic islet survival, PLoS One, 12, e0183780, 10.1371/journal.pone.0183780 · DOI · Paper page
  47. Sachlos, 2008, Embryoid body morphology influences diffusive transport of inductive biochemicals: a strategy for stem cell differentiation, Biomaterials, 29, 4471, 10.1016/j.biomaterials.2008.08.012 · DOI
  48. Nath, 2017, Size- and time-dependent growth properties of human induced pluripotent stem cells in the culture of single aggregate, J Biosci Bioeng, 124, 469, 10.1016/j.jbiosc.2017.05.006 · DOI
  49. Kato, 2018, Comparison of growth kinetics between static and dynamic cultures of human induced pluripotent stem cells, J Biosci Bioeng, 125, 736, 10.1016/j.jbiosc.2018.01.002 · DOI
  50. Kim, 2018, Adv Exper Med and Bio, 19
  51. Kim, 2018, Role of cell-secreted extracellular matrix formation in aggregate formation and stability of human induced pluripotent stem cells in suspension culture, J Biosci Bioeng, 127, 372, 10.1016/j.jbiosc.2018.08.010 · DOI
  52. Nogueira, 2019, Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel™ bioreactors, J Biol Eng, 13, 1, 10.1186/s13036-019-0204-1 · DOI · Paper page
  53. Toyoda, 2015, Cell aggregation optimizes the differentiation of human ESCs and iPSCs into pancreatic bud-like progenitor cells, Stem Cell Res, 14, 185, 10.1016/j.scr.2015.01.007 · DOI · Paper page
  54. Pipeleers, 1985, Interplay of nutrients and hormones in the regulation of insulin release, Endocrinology, 117, 824, 10.1210/endo-117-3-824 · DOI · Paper page
  55. Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37), Nature, 361, 362, 10.1038/361362a0 · DOI · Paper page
  56. Capozzi, 2019, β-Cell tone is defined by proglucagon peptides through cyclic AMP signaling, JCI Insight, 4, e126742, 10.1172/jci.insight.126742 · DOI · Paper page
  57. Svendsen, 2018, Insulin secretion depends on intra-islet glucagon signaling, Cell Rep, 25, 1127, 10.1016/j.celrep.2018.10.018 · DOI · Paper page
  58. Chowdhury, 2013, Functional differences between aggregated and dispersed insulin-producing cells, Diabetologia, 56, 1557, 10.1007/s00125-013-2903-3 · DOI · Paper page
  59. King, 2007, Normal relationship of beta- and non-beta-cells not needed for successful islet transplantation, Diabetes, 56, 2312, 10.2337/db07-0191 · DOI · Paper page
  60. Pipeleers, 1991, Transplantation of purified islet cells in diabetic rats: I. Standardization of islet cell grafts, Diabetes, 40, 908, 10.2337/diab.40.7.908 · doi:10.2337/diab.40.7.908
  61. Kieffer, 2016, Closing in on mass production of mature human beta cells, Cell Stem Cell, 18, 699, 10.1016/j.stem.2016.05.014 · DOI
  62. Ionescu-Tirgoviste, 2015, A 3D map of the islet routes throughout the healthy human pancreas, Sci Rep, 5, 10.1038/srep14634 · DOI · Paper page
  63. Kim, 2009, Islet architecture: a comparative study, Islets, 1, 129, 10.4161/isl.1.2.9480 · DOI · Paper page
  64. Lehmann, 2007, Superiority of small islets in human islet transplantation, Diabetes, 56, 594, 10.2337/db06-0779 · DOI · Paper page
  65. Macgregor, 2006, Small rat islets are superior to large islets in in vitro function and in transplantation outcomes Rat Islet Isolation and Separation Procedures, Am J Physiol Endocrinol Metab, 290, 771, 10.1152/ajpendo.00097.2005 · DOI · Paper page
  66. Fujita, 2011, Large human islets secrete less insulin per islet equivalent than smaller islets in vitro, Islets, 3, 1, 10.4161/isl.3.1.14131 · DOI
  67. Su, 2010, Small islets are essential for successful intraportal transplantation in a diabetes mouse model, Scand J Immunol, 72, 504, 10.1111/j.1365-3083.2010.02466.x · DOI
  68. Farhat, 2013, Small human islets comprised of more β-cells with higher insulin content than large islets, Islets, 5, 87, 10.4161/isl.24780 · DOI
  69. Yu, 2018, Bioengineered human pseudoislets form efficiently from donated tissue, compare favourably with native islets in vitro and restore normoglycaemia in mice, Diabetologia, 61, 2016, 10.1007/s00125-018-4672-5 · DOI · Paper page
  70. Ichihara, 2016, Size effect of engineered islets prepared using microfabricated wells on islet cell function and arrangement, Heliyon, 2, 10.1016/j.heliyon.2016.e00129 · DOI
  71. Cogger, 2017, Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitors, Nat Commun, 8, 331, 10.1038/s41467-017-00561-0 · DOI · Paper page
  72. Ameri, 2017, Efficient generation of glucose-responsive beta cells from isolated GP2+ human pancreatic progenitors, Cell Rep, 19, 36, 10.1016/j.celrep.2017.03.032 · DOI · Paper page
  73. Stock, 2019, Conformal coating of stem cell-derived islets for β cell replacement in type 1 diabetes, Stem Cell Rep, 14, 91, 10.1016/j.stemcr.2019.11.004 · DOI · Paper page
  74. Bandeiras, 2019, Bringing stem cell-based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis, Biotechnol J, 14, 10.1002/biot.201800563 · DOI
  75. Archibald, 2015, Using the cost-effectiveness of allogeneic islet transplantation to inform induced pluripotent stem cell-derived β-cell therapy reimbursement, Regen Med, 10, 959, 10.2217/rme.15.59 · DOI
  76. Bandeiras, 2019, Economics of beta-cell replacement therapy, Curr Diab Rep, 19, 1, 10.1007/s11892-019-1203-9 · DOI
  77. Iworima, 2021, Process parameter development for the scaled generation of stem cell-derived pancreatic endocrine cells, STEM CELLS Transl Med, 10, 1459, 10.1002/sctm.21-0161

Cited by

See all 18

Metadata

Authors
Iworima, D. G., Rieck, S., & Kieffer, T. J.
Venue
Stem Cells Translational Medicine
Published
2021-08-13
Volume
10
Issue
11
Pages
1459-1469
ISSN
  • 2157-6564
  • 2157-6580
Cited by
18
References
22
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.